Key facts
- A federal health advisory panel narrowly recommended easing restrictions on several injectable peptides.
- The panel voted 8-6 to suggest placing peptides like BPC-157, TB-500, and KPV on the FDA's list for pharmacy compounding.
- FDA scientists raised concerns about the lack of data proving the safety and efficacy of these peptides for medical use.
- The panel's recommendation is advisory and not binding for the FDA.
- Health secretary Robert F Kennedy Jr is a known supporter of peptides and has previously sought to overturn FDA restrictions.
A panel of federal health advisers narrowly recommended easing restrictions on several injectable peptides, including BPC-157, TB-500, and KPV, despite warnings from FDA scientists about their unproven safety and efficacy. The panel voted 8-6, with one abstention, in favor of allowing pharmacies to compound these substances. This recommendation could embolden Health Secretary Robert F Kennedy Jr, who has publicly supported peptides and previously aimed to overturn FDA restrictions. The panel's vote is advisory, but the FDA typically considers such recommendations. Members with industry ties largely voted in favor, while those from academic backgrounds expressed concerns about market-driven demand over scientific evidence. Medical experts describe the current peptide market as unregulated and potentially harmful.